Aqix Limited Logo AQIX® Fluid Technology.
Designed-Developed-Patented-Manufactured.
The World's Only Synthetic Human Interstitial Fluid


Latest news:

JUNE 2011

Aqix Limited is awarded a Research and Development Grant from the Technology Strategy Board for intravenous application of AQIX® RS-I.

AUGUST 2011

Aqix Limited patent for the intravenous application of AQIX® RS-I is granted in South Africa.

APRIL 2012

Aqix Limited is to participate as an SME member of the Consortium on Organ Preservation in Europe (COPE) grant award for €5.9M during 2013-17 to provide AQIX® RS-I as the base solution in the quest for improved, normothermic graft preservation of human donor organs.

DECEMBER 2012

Aqix Limited receives a notification of intent from the European Patent Office to be granted a EU patent filed in July, 2008, for applications of AQIX® RS-I involving blood/body fluid volume replacement therapies.

 

FEBRUARY 2013

European Patent Office grants Aqix Ltd a EU patent for intravenous applications of AQIX® RS-I involving blood/body fluid volume replacement therapies.



Homeostasis


Homeostasis is a set of multiple, dynamic equilibrium adjustments intricately controlled by interrelated regulatory mechanisms.

Cell Membrane

Cellular homeostasis is key to regulating the internal and external environments of any cell. It is essential for keeping cells energized and maintaining all aspects of cellular functions, in particular, enzyme processes, cell membranes and receptor sensitivity.

Homeostasis within the tissue means maintaining all constituent cells so as to retain cell-cell interactions. The most important of these interactions is between neurons and the organs they innervate.

The AQIX® RS-I platform fluid technology uniquely maintains homeostasis at cellular, tissue and organ levels. It does this by replicating the essential, intercellular conditions surrounding each cell membrane and is suitable for all cell types.

AQIX® RS-I is formulated to maintain all aspects of cellular function from autoregulatory mechanisms to the Krebs cycle and ADP:ATP balance. It has been demonstrated that the glycolytic pathway is sustained by AQIX® RS-I even under periods of ischemia and anaerobic metabolism. These are all essential requisites for maintaining cell viability.